Discovery R&D Title The Global Structure of Prostate Cancer R&D Sub title Author BioSeeker Publication date September 2003 ISBN - n/a - Pages 250 Price pdf £1220   |   print n/a Summary The Global Structure of Prostate Cancer R&D is one of the most comprehensive information sources currently available in the prostate cancer R&D arena. Information about innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report will give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current prostate cancer pipeline. Included in this report: Information on more that 160 companies active in prostate cancer R&D Information on more that 300 industry related prostate cancer projects Data from 170 clinical trials Information on more than 130 preclinical projects 92 graphs illustrating the most important relations between types of therapy, effects and mechanisms Advanced analysis of general and specific trends in the pipeline Some of the companies analysed in this report include: Abbott Laboratories, AEterna Laboratories, Alfacell, AlphaVax, ALZA, Aronex Pharmaceuticals, AstraZeneca, Aventis, AVI BioPharma, Baxter, Biogen, BioVex, Bristol-Myers Squibb Co, Celera Genomics, Celgene, Cell Therapeutics, CellGenix, Cephalon, Corautus, Corixa, Coulter Pharmaceutical, Cytel, Dendreon, Eli Lilly & Co, F Hoffmann-La Roche, Fujisawa Pharmaceuticals, Genentech, GlaxoSmithKline, GTx, Hybridon, IDEC Pharma, ILEX Oncology, ImClone/BMS/Merck, Immunex, Immunomedics, ISIS Pharmaceuticals, Maxim Pharmaceuticals, Medarex, Millennium, ML Laboratories, Novogen, Oncology Sciences, Paladin Labs, Pfizer, Pharmacia, PSMA Development Company (PDC), Roche Holding, Seattle Genetics, Takeda Chemical Industries, Transgene, Wyeth Pharmaceuticals, Yamanouchi Pharmaceutical Co, YM Biosciences. The Global Structure of Prostate Cancer R&D is an excellent source of information providing a solid presentation of exciting and rapidly evolving therapeutics and enabling companies to establish potential partners and competitors. This report will assist you in: Tracking cutting edge companies, therapies and new technologies Rapid identification of partners & competitors Laying down a comprehensive framework for further analysis of the field Producing presentations surrounding the development of prostate cancer therapeutics Identifying emerging prostate cancer products & key areas of pharmaceutical R&D TABLE OF CONTENTS Contents Executive Summary Methodology and Descriptions Intoduction Information Structures List of Tables Table 1. Emerging cancer therapies Table 2. Key trends that will drive the oncology market in the near future Table 3. Companis: Summarizing the Field of Prostate Cancer R&D in Relation to Company Table 4. Stage: Summarizing the Field of Prostate Cancer R&D in Relation to Stage Table 5. Effect: Summarizing the Field of Prostate Cancer R&D in Relation to Effect Table 6. Therapy: Summarizing the Field of Prostate Cancer R&D in Relation to Therapy Table 7. Mechanism: Summarizing the Field of Prostate Cancer R&D in Relation to Mechanism Table 8. Early/Late Stage: Summarizing the Field of Prostate Cancer R&D in Relation to Early (Preclinical to Phase I/II) and Late (Phase II/III to Phase III) Stage Table 9. Summary of the Number of Projects for each Company in Relation to Stage Table 10. Summary of the Number of Projects for each Company in Relation to Therapeutic Effect Table 11. Summary of the Number of Projects for each Company in Relation to Therapy Given Table 12. Summary of the Number of Projects for each Therapeutic Effect in Relation to Stage Table 13. Summary of the Number of Projects for each Therapy Given in Relation to Stage Table 14. Summary of the Number of Projects for each Mechanism in Relation to Stage List of Figures Picture 1. Expected growth of global oncology market Picture 2. Number of Antiangiogenesis Projects in Relation to Stage Picture 3. Number of Apoptosis Projects in Relation to Stage Picture 4. Number of Cytotoxic Projects in Relation to Stage Picture 5. Number of Growth Inhibition Projects in Relation to Stage Picture 6. Number of Hormonal Therapy Projects in Relation to Stage Picture 7. Number of Immunotherapy Projects in Relation to Stage Picture 8. Number of Preclinical Projects in Relation to Effect Picture 9. Number of Phase I Projects in Relation to Effect Picture 10. Number of Phase I/II Projects in Relation to Effect Picture 11. Number of Phase II Projects in Relation to Effect Picture 12. Number of Phase II/III Projects in Relation to Effect Picture 13. Number of Phase III Projects in Relation to Effect Picture 14. Number of Antisense Projects in Relation to Stage Picture 15. Number of Biological Projects in Relation to Stage Picture 16. Number of Cell Therapy Projects in Relation to Stage Picture 17. Number of Gene Therapy Projects in Relation to Stage Picture 18. Number of Monoclonal Antibody Projects in Relation to Stage Picture 19. Number of Small Molecular Drug Projects in Relation to Stage Picture 20. Number of Preclinical Projects in Relation to Therapy Given Picture 21. Number of Phase I Projects in Relation to Therapy Given Picture 22. Number of Phase I/II Projects in Relation to Therapy Given Picture 23. Number of Phase II Projects in Relation to Therapy Given Picture 24. Number of Phase II/III Projects in Relation to Therapy Given Picture 25. Number of Phase III Projects in Relation to Therapy Given Picture 26. Number of Tumor Antigen Projects in Relation to Effect Picture 27. Number of Antiangiogenesis Projects in Relation to Mechanism Picture 28. Number of Apoptosis Projects in Relation to Mechanism Picture 29. Number of Cytotoxic Projects in Relation to Mechanism Picture 30. Number of Growth Inhibition Projects in Relation to Mechanism Picture 31. Number of Hormonal Therapy Projects in Relation to Mechanism Picture 32. Number of Immunotherapy Projects in Relation to Mechanism Picture 33. Number of Bcl-2 Projects in Relation to Therapy Given Picture 34. Number of Cell-Cycle Inhibitor Projects in Relation to Therapy Given Picture 35. Number of Cytokine Projects in Relation to Therapy Given Picture 36. Number of DNA Targeting Projects in Relation to Therapy Given Picture 37. Number of EGF Antagonist Projects in Relation to Therapy Given Picture 38. Number of GNRH/LHRH Agonist Projects in Relation to Therapy Given Picture 39. Number of GNRH/LHRH Antagonist Projects in Relation to Therapy Given Picture 40. Number of Microtubuli Projects in Relation to Therapy Given Picture 41. Number of p53 Projects in Relation to Therapy Given Picture 42. Number of Radiotherapy Projects in Relation to Therapy Given Picture 43. Number of Tumor Antigen Projects in Relation to Therapy Given Picture 44. Number of VEGF Antagonist Projects in Relation to Therapy Given Picture 45. Number of Antisense Projects in Relation to Mechanism Picture 46. Number of Biological Projects in Relation to Mechanism Picture 47. Number of Cell Therapy Projects in Relation to Mechanism Picture 48. Number of Gene Therapy Projects in Relation to Mechanism Picture 49. Number of Monoclonal Antibody Projects in Relation to Mechanism Picture 50. Number of Small Molecular Drug Projects in Relation to Mechanism Picture 51. Number of Antisense Projects in Relation to Effect Picture 52. Number of Biological Projects in Relation to Effect Picture 53. Number of Cell Therapy Projects in Relation to Effect. Picture 54. Number of Gene Therapy Projects in Relation to Effect Picture 55. Number of Monoclonal Antibody Projects in Relation to Effect Picture 56. Number of Small Molecular Drug Projects in Relation to Effect Picture 57. Number of Antiangiogenesis Projects in Relation to Therapy Given Picture 58. Number of Apoptosis Projects in Relation to Therapy Given Picture 59. Number of Cytotoxic Projects in Relation to Therapy Given Picture 60. Number of Growth Inhibition Projects in Relation to Therapy Given Picture 61. Number of Hormonal Therapy Projects in Relation to Therapy Given Picture 62. Number of Immunotherapy Projects in Relation to Therapy Given Picture 63. Clinical Pipeline Trends in Relation to Effect Picture 64. Clinical Pipeline Trends in Relation to Therapy Given Picture 65. Clinical Pipeline Trends in Relation to Mechanism Picture 66. Antiangiogenesis Clinical Pipeline Trends in Relation to Mechanism Picture 67. Antiangiogenesis Clinical Pipeline Trends in Relation to Therapy Given Picture 68. Apoptosis Clinical Pipeline Trends in Relation to Mechanism Picture 69. Apoptosis Clinical Pipeline Trends in Relation to Therapy Given Picture 70. Cytotoxic Clinical Pipeline Trends in Relation to Mechanism Picture 71. Cytotoxic Clinical Pipeline Trends in Relation to Therapy Given Picture 72. Growth Inhibition Clinical Pipeline Trends in Relation to Mechanism Picture 73. Growth Inhibition Clinical Pipeline Trends in Relation to Therapy Given Picture 74. Hormonal Therapy Clinical Pipeline Trends in Relation to Mechanism Picture 75. Hormonal Therapy Clinical Pipeline Trends in Relation to Therapy Given Picture 76. Immunotherapy Clinical Pipeline Trends in Relation to Mechanism Picture 77. Immunotherapy Clinical Pipeline Trends in Relation to Therapy Given Picture 78. Antisense Clinical Pipeline Trends in Relation to Effect Picture 79. Biologicals Clinical Pipeline Trends in Relation to Effect Picture 80. Biologicals Clinical Pipeline Trends in Relation to Mechanism Picture 81. Gene Therapy Clinical Pipeline Trends in Relation to Effect Picture 82. Gene Therapy Clinical Pipeline Trends in Relation to Mechanism Picture 83. Monoclonal Antibody Clinical Pipeline Trends in Relation to Effect Picture 84. Monoclonal Antibody Clinical Pipeline Trends in Relation to Mechanism Picture 85. Small Molecular Drugs Clinical Pipeline Trends in Relation to Effect Picture 86. Small Molecular Drugs Clinical Pipeline Trends in Relation to Mechanism Other Clinical Pipeline Trends Picture 87. DNA Targeting Clinical Pipeline Trends in Relation to Other Mechanisms Picture 88. Protein Kinase Inhibitor Clinical Pipeline Trends in Relation to Effect Picture 89. Protein Kinase Inhibitor Clinical Pipeline Trends in Relation to Mechanism Early vs. Late Stage Pipeline R&D Trends Picture 90. Pipeline Trends in Relation to Effect Picture 91. Pipeline Trends in Relation to Therapy Given Picture 92. Pipeline Trends in Relation to Mechanism Discovery R&D

No additional author information available for this product